{"id":120298,"date":"2025-12-29T22:36:06","date_gmt":"2025-12-29T22:36:06","guid":{"rendered":"https:\/\/www.europesays.com\/se\/120298\/"},"modified":"2025-12-29T22:36:06","modified_gmt":"2025-12-29T22:36:06","slug":"pila-pharma-inleder-prekliniska-fetmastudier-med-xen-d0501","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/120298\/","title":{"rendered":"Pila Pharma inleder prekliniska fetmastudier med XEN-D0501"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Bioteknikbolaget Pila Pharma har som planerat inlett planerade prekliniska studier i fetma med l\u00e4kemedelskandidaten XEN-D0501, en TRPV1-h\u00e4mmare.\n <\/p>\n<p>Studierna genomf\u00f6rs p\u00e5 tv\u00e5 olika typer av \u00f6verviktiga r\u00e5ttor f\u00f6r att st\u00e4rka datakvaliteten och visa effekt p\u00e5 kroppsvikt och relaterade tillst\u00e5nd. Studierna p\u00e5g\u00e5r i 28 dagar, vilket inneb\u00e4r att resultaten v\u00e4ntas inom kort och, som tidigare kommunicerats, f\u00f6re bolagets kommande teckningsoptionsperiod i februari 2026.\n <\/p>\n<p>Vd Gustav Gram kommenterar \u00e4ven n\u00e4sta steg, givet ett positivt utfall i studien:\n <\/p>\n<p>\u201dDetta \u00e4r naturligtvis beroende av finansiering, men med ytterligare positiva data som tillf\u00f6rs v\u00e5rt befintliga datamaterial \u2013 vilket redan omfattar en betydande m\u00e4ngd kliniska data \u2013 bed\u00f6mer vi att vi \u00e4r v\u00e4l positionerade f\u00f6r att s\u00e4kra finansiering f\u00f6r n\u00e4sta steg. Finansieringen kan komma fr\u00e5n TO2-teckningsoptioner, en riktad nyemission eller genom finansiering via ett partnerskap. Enligt v\u00e5r nuvarande planering kommer den fortsatta utvecklingen att omfatta kliniska studier p\u00e5 personer med fetma samt p\u00e5 personer med fetma och typ 2-diabetes.\u201d\n <\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">newsroom@finwire.se<br \/>\n <br class=\"col-start-2\"\/><br \/>\n Nyhetsbyr\u00e5n Finwire<\/p>\n","protected":false},"excerpt":{"rendered":"Bioteknikbolaget Pila Pharma har som planerat inlett planerade prekliniska studier i fetma med l\u00e4kemedelskandidaten XEN-D0501, en TRPV1-h\u00e4mmare. Studierna&hellip;\n","protected":false},"author":2,"featured_media":119816,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[72,70,71,34,31,33,32,30],"class_list":{"0":"post-120298","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ekonomi","8":"tag-business","9":"tag-economy","10":"tag-ekonomi","11":"tag-se","12":"tag-svenska","13":"tag-sverige","14":"tag-sweden","15":"tag-swedish"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115805250027241129","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/120298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=120298"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/120298\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/119816"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=120298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=120298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=120298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}